Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn’s disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn’s disease activity index (...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2015/793764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173386699833344 |
|---|---|
| author | Lijuan Yu Xuehua Yang Lu Xia Jie Zhong Wensong Ge Jianxin Wu Hongchun Liu Fei Liu Zhanju Liu |
| author_facet | Lijuan Yu Xuehua Yang Lu Xia Jie Zhong Wensong Ge Jianxin Wu Hongchun Liu Fei Liu Zhanju Liu |
| author_sort | Lijuan Yu |
| collection | DOAJ |
| description | This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn’s disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn’s disease activity index (CDAI) < 150. Clinical response was assessed by a decrease in CDAI ≥ 70, and the failure as a CDAI was not significantly changed or increased. Ten weeks after therapy, 61 (57.5%) patients achieved clinical remission, 17 (16.0%) had clinical response, and the remaining 28 (26.4%) were failed. In remission group, significant changes were observed in CDAI, the Simple Endoscopic Score for Crohn’s Disease (SES-CD), and serum indexes. Patients with short disease duration (22.2 ± 23.2 months) and luminal lesions showed better effects compared to those with long disease duration (71.0 ± 58.2 months) or stricturing and penetrating lesions. IFX markedly downregulated Th1/Th17-mediated immune response but promoted IL-25 production in intestinal mucosa from remission group. No serious adverse events occurred to terminate treatment. Taken together, our studies demonstrated that IFX is efficacious and safe in inducing clinical remission, promoting mucosal healing, and downregulating Th1/Th17-mediated immune response in short course CD patients with luminal lesions. |
| format | Article |
| id | doaj-art-c9a19ec8d4de4a82a6061bdaba3b9653 |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-c9a19ec8d4de4a82a6061bdaba3b96532025-08-20T02:19:51ZengWileyMediators of Inflammation0962-93511466-18612015-01-01201510.1155/2015/793764793764Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut MucosaLijuan Yu0Xuehua Yang1Lu Xia2Jie Zhong3Wensong Ge4Jianxin Wu5Hongchun Liu6Fei Liu7Zhanju Liu8Department of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaDepartment of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaDepartment of Gastroenterology, Ruijin Hospital of Shanghai Jiaotong University, Shanghai 200025, ChinaDepartment of Gastroenterology, Ruijin Hospital of Shanghai Jiaotong University, Shanghai 200025, ChinaDepartment of Gastroenterology, Xinhua Hospital of Shanghai Jiaotong University, Shanghai 200092, ChinaDepartment of Gastroenterology, Xinhua Hospital of Shanghai Jiaotong University, Shanghai 200092, ChinaDepartment of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, ChinaDepartment of Gastroenterology, East Hospital of Tongji University, Shanghai 200120, ChinaDepartment of Gastroenterology, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, ChinaThis study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn’s disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn’s disease activity index (CDAI) < 150. Clinical response was assessed by a decrease in CDAI ≥ 70, and the failure as a CDAI was not significantly changed or increased. Ten weeks after therapy, 61 (57.5%) patients achieved clinical remission, 17 (16.0%) had clinical response, and the remaining 28 (26.4%) were failed. In remission group, significant changes were observed in CDAI, the Simple Endoscopic Score for Crohn’s Disease (SES-CD), and serum indexes. Patients with short disease duration (22.2 ± 23.2 months) and luminal lesions showed better effects compared to those with long disease duration (71.0 ± 58.2 months) or stricturing and penetrating lesions. IFX markedly downregulated Th1/Th17-mediated immune response but promoted IL-25 production in intestinal mucosa from remission group. No serious adverse events occurred to terminate treatment. Taken together, our studies demonstrated that IFX is efficacious and safe in inducing clinical remission, promoting mucosal healing, and downregulating Th1/Th17-mediated immune response in short course CD patients with luminal lesions.http://dx.doi.org/10.1155/2015/793764 |
| spellingShingle | Lijuan Yu Xuehua Yang Lu Xia Jie Zhong Wensong Ge Jianxin Wu Hongchun Liu Fei Liu Zhanju Liu Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa Mediators of Inflammation |
| title | Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa |
| title_full | Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa |
| title_fullStr | Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa |
| title_full_unstemmed | Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa |
| title_short | Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa |
| title_sort | infliximab preferentially induces clinical remission and mucosal healing in short course crohn s disease with luminal lesions through balancing abnormal immune response in gut mucosa |
| url | http://dx.doi.org/10.1155/2015/793764 |
| work_keys_str_mv | AT lijuanyu infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT xuehuayang infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT luxia infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT jiezhong infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT wensongge infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT jianxinwu infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT hongchunliu infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT feiliu infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa AT zhanjuliu infliximabpreferentiallyinducesclinicalremissionandmucosalhealinginshortcoursecrohnsdiseasewithluminallesionsthroughbalancingabnormalimmuneresponseingutmucosa |